Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sanochemia Pharmazeutika
Neufeld an der Leitha, Burgenland, Austriasanochemia.com ↗
- Ownership
- Private
- Employees
- ~130
- Development stage
- Other
01
Overview
Sanochemia has reached pivotal late Phase III for Ferrotran® (ferumoxtran) MRI contrast agent for detection of lymph node metastases in prostate cancer, with deployment in named-patient-use programs (>700 patients diagnosed). Its legacy APIs (e.g., galantamine hydrobromide for Alzheimer’s) are commercialized, and it operates as a CDMO for sterile injectables and small molecule APIs.
- Therapeutic areas
- OncologyNeurologyOther
- Modalities
- Small moleculeNanoparticleBiologic (as APIs manufactured for clients)
- Industry
- Biotech
02
Partnerships
SPL Medical (licensing for Ferrotran® MRI agent)b.e.imaging (development/distribution agreement for Resotran® MRI agent)
Beyond the preview
Go deeper on Sanochemia Pharmazeutika.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sanochemia Pharmazeutika.